TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30760231

Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention (multicomponent intervention including organizational, work environmental, and individual elements)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 250
Study: 27679962

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26391671

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) + low-dose ethinyl estradiol (EE) (0.05 mg daily for 5 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) + placebo
Number of subjects: 95
Study: 23176437

Group type: EXPERIMENTAL
Intervention: Light and moderate alcohol consumption of key participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (abstainers)
Number of subjects: 0
Study: 21349248

Group type: EXPERIMENTAL
Intervention: Implicit measures of liking for nicotine after 12 hours of deprivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit measures of wanting for nicotine after 12 hours of deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implicit measures of wanting and liking for nicotine
Number of subjects: 0
Study: 19022694

Group type: EXPERIMENTAL
Intervention: agalsidase beta (Fabrazyme) at 1mg/kg every 2 weeks for up to 5 years
Number of subjects: 134
Study: 17355735

Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination therapy (Dronabinol 10-20 mg, Ondansetron 8-16 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 64
Study: 15300183

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.1 mg/kg po bid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11372667

Group type: EXPERIMENTAL
Intervention: HRT (2 mg 17‐beta‐estradiol plus 1 mg norethisterone acetate for 24 months)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 9566276

Group type: EXPERIMENTAL
Intervention: Synthetic tetrahydrocannabinol (THC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study: 7536691

Group type: EXPERIMENTAL
Intervention: Radically resected patients
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Bypassed patients
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Patients with advanced disease
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 'Good risk' bypassed patients (stage I-III)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Bypassed groups
Number of subjects: 233
Study: 2655500

Group type: EXPERIMENTAL
Intervention: Needle bevel oriented perpendicular to longitudinal dural fibers
Number of subjects: 41

Group type: COMPARATOR
Intervention: Needle bevel oriented parallel to longitudinal dural fibers
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Therapeutic blood patch administered to perpendicular group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Therapeutic blood patch administered to parallel group
Number of subjects: 41
Study: 355181

Group type: EXPERIMENTAL
Intervention: Butaclamol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 24
Study: 31201479

Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dronabinol (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone (5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxycodone (0, 5, 10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dronabinol (0, 2.5, 5 mg)
Number of subjects: 10
Study: 27959717

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily)
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 13885

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885
Study: 25234100

Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Daylight phototherapy
Number of subjects: 150
Study: 24652498

Group type: EXPERIMENTAL
Intervention: Chloroquine-azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study: 23040652

Group type: EXPERIMENTAL
Intervention: G1: 20mL L+10mL M
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: G2: 10mL L+20mL M
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: G3: 15mL L+15mL M
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 19888533

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (testosterone undecanoate 1,000 mg, intramuscular injections, 5 injections over 40 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17301632

Group type: EXPERIMENTAL
Intervention: 6-month training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not trained (control group)
Number of subjects: 50
Study: 15333077

Group type: EXPERIMENTAL
Intervention: Brugada syndrome patients with VA induced by PES
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Brugada syndrome patients without VA
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 15
Study: 11121982

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 228
Study: 9872339

Group type: EXPERIMENTAL
Intervention: Intravenous rizatriptan (0.5-5 mg)
Number of subjects: 0
Study: 7523132

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT) for 1 hour
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transurethral catheter therapy for 1 hour (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transurethral catheter therapy (Control)
Number of subjects: 40
Study: 2802836

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human growth hormone (GH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30515674

Group type: EXPERIMENTAL
Intervention: palbociclib (125 mg/day [3 weeks on/1 week off]) plus letrozole (2.5 mg daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo plus letrozole
Number of subjects: 46
Study: 28455600

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg oral preoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo oral preoperatively
Number of subjects: 60
Study: 25840467

Group type: EXPERIMENTAL
Intervention: Inhibition training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention training
Number of subjects: 0
Study: 23046593

Group type: EXPERIMENTAL
Intervention: Right transradial approach (RTA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Left transradial approach (LTA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Procedures needing >2 catheters
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increasing number of catheters
Number of subjects: 40
Study: 21208583

Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 334

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Nonremitters
Number of subjects: 334
Study: 18359622

Group type: EXPERIMENTAL
Intervention: 0.3% dehydroepiandrosterone (DHEA) applied twice daily for 12 months
Number of subjects: 150
Study: 17238472

Group type: EXPERIMENTAL
Intervention: computer-based patient 'roadmap'
Number of subjects: 20800000
Study: 12730532

Group type: EXPERIMENTAL
Intervention: 3-monthly i.v. ibandronate (2 mg) bolus injections
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oral daily alfacalcidol (1 micro g)
Number of subjects: 104
Study: 11361273

Group type: EXPERIMENTAL
Intervention: Ayurvedic therapeutics (AT)
Number of subjects: 0
Study: 9299911

Group type: EXPERIMENTAL
Intervention: Left hemisphere group (attended left ear)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Right hemisphere group (attended right ear)
Number of subjects: 100
Study: 8291115

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte serum (RATS)
Number of subjects: 166

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 166
Study: 2833090

Group type: COMPARATOR
Intervention: Lisinopril alone (group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lisinopril plus hydrochlorothiazide (group B)
Number of subjects: 26
Study: 31694364

Group type: EXPERIMENTAL
Intervention: Nordic walking and cognitive training (group NW+C)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nordic walking classes (group NW)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 61
Study: 28400163

Group type: EXPERIMENTAL
Intervention: Stress condition prior to extinction learning
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control condition prior to extinction learning
Number of subjects: 49
Study: 26335224

Group type: EXPERIMENTAL
Intervention: 37.5 mg daily sunitinib therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline FDG-PET
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline FLT-PET
Number of subjects: 20
Study: 22903515

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 μg every 6 h)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 μg every 6 h)
Number of subjects: 134
Study: 21505939

Group type: EXPERIMENTAL
Intervention: Combined whole body vibration and balance training
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comprehensive inpatient geriatric rehabilitation program
Number of subjects: 66
Study: 19175963

Group type: EXPERIMENTAL
Intervention: Acupuncture at sites reported to cause onset of labour
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham acupuncture at nearby sites
Number of subjects: 16
Study: 16497616

Group type: EXPERIMENTAL
Intervention: Duodenal lipids during jejunal gas challenge
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duodenal amino acids during jejunal gas challenge
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duodenal lipids during ileal gas challenge
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duodenal amino acids during ileal gas challenge
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duodenal glucose during jejunal gas challenge
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duodenal glucose during ileal gas challenge
Number of subjects: 32
Study: 12929021

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with histological and cytological evaluation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with cytological examination
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with histological assessment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with combined modalities
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EUS‐FNA
Number of subjects: 41
Study: 10689266

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 9496289

Group type: EXPERIMENTAL
Intervention: Near patient testing (NPT) of whole blood sample
Number of subjects: 306

Group type: COMPARATOR
Intervention: Routine method (courier transport of citrated sample to the laboratory for analysis)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control method (plasma separated and frozen in liquid nitrogen, transported to the laboratory)
Number of subjects: 306
Study: 8449053

Group type: EXPERIMENTAL
Intervention: Breathing cold air (-13 degrees C)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 19
Study: 3307440

Group type: EXPERIMENTAL
Intervention: +1.00 D add bifocals
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: +2.00 D add bifocals
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Single vision lenses
Number of subjects: 207
Study: 30458838

Group type: EXPERIMENTAL
Intervention: BMI intervention with bihemispheric beta activity and adaptive support vector machine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Decoding based on brain activity
Number of subjects: 37
Study: 27635998

Group type: EXPERIMENTAL
Intervention: Computerized cognitive exercise training (CT)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Computerized relaxation (control)
Number of subjects: 213
Study: 25542295

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg/mL three‐times weekly (GA40)
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study: 24005315

Group type: EXPERIMENTAL
Intervention: Vitamin D3 5000 IU/week
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vitamin D3 7000 IU/week
Number of subjects: 39

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GHD patients with 25(OH)D ≥15 ng/ml
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GHD patients with 25(OH)D <15 ng/ml
Number of subjects: 39
Study: 20961422

Group type: EXPERIMENTAL
Intervention: 5.83 mg/mL liquid formulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8.0 mg/mL liquid formulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Freeze-dried (FD) formulation
Number of subjects: 30
Study: 17890048

Group type: EXPERIMENTAL
Intervention: Eye movement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Eye movement with distancing instruction
Number of subjects: 48

Group type: COMPARATOR
Intervention: Therapist instructions (reliving or distancing)
Number of subjects: 48
Study: 16904048

Group type: EXPERIMENTAL
Intervention: Management with PAC
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Management without PAC (Control)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Economic evaluation of PAC
Number of subjects: 1014
Study: 12750540

Group type: EXPERIMENTAL
Intervention: Thrombolytics
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 23
Study: 10994151

Group type: EXPERIMENTAL
Intervention: Test formulation (amlodipine tablet broken into two halves and encapsulated)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation (amlodipine tablet broken into two halves and ingested as such)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Test formulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 18
Study: 8681596

Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms/kg iv)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2001018

Group type: EXPERIMENTAL
Intervention: Desflurane 3% (approximately 0.5 MAC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Isoflurane 0.6% (approximately 0.5 MAC)
Number of subjects: 38
Study: 6135507

Group type: EXPERIMENTAL
Intervention: Lormetazepam (1 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amobarbital sodium (100 mg)
Number of subjects: 50
Study: 30998125

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control Group (Normoglycemic)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both MICT and SIT
Number of subjects: 54
Study: 29327213

Group type: EXPERIMENTAL
Intervention: Adjunctive curcumin (500 to 1500 mg/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adjunctive curcumin
Number of subjects: 65
Study: 26701171

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cognitive‐Behavioral Therapy (CBT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 180
Study: 24152823

Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure level (SBPL)
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Lower carotid distensibility
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Higher carotid-femoral pulse wave velocity
Number of subjects: 1087
Study: 22374612

Group type: EXPERIMENTAL
Intervention: Perfusion group (DXM 2.5 mg/0.5 ml perfused transtympanically for 1 h twice a day for 7 days, total 35.0 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Injection group (DXM 2.5 mg injected by tympanic membrane puncture at intervals of 2 days for a total of 4 occasions, total 10.0 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Drip group (DXM 2.5 mg/0.5 ml dripped via a ventilation tube once on the first day and twice a day for the remaining 6 days, total 32.5 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study: 20595201

Group type: EXPERIMENTAL
Intervention: Nutritive solutions (sucrose and NaCl)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Harmful solutions (quinine and capsaicin)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tasteless control solution
Number of subjects: 16
Study: 18341178

Group type: EXPERIMENTAL
Intervention: Combined treatment of 2 NRTI + 1 NNRTI (51%), 3 NRTI (45%), 2 NRTI + 1 PI (4%)
Number of subjects: 112
Study: 16619818

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Gentamycin
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 166
Study: 12067838

Group type: EXPERIMENTAL
Intervention: R-beta-hydroxybutyrate infusion
Number of subjects: 12
Study: 10215759

Group type: EXPERIMENTAL
Intervention: Non-electrostatic Babyhaler (coated with benzalkonium chloride)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: New Babyhaler (rinsed in water)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: New AeroChamber (rinsed in water)
Number of subjects: 5
Study: 8550258

Group type: EXPERIMENTAL
Intervention: Effleurage massage of the quadriceps muscles for four days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control leg (no massage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effleurage massage of the quadriceps muscles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light quadriceps muscle contractions
Number of subjects: 0
Study: 2225290

Group type: EXPERIMENTAL
Intervention: Enflurane-N2O anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane-N2O anaesthesia
Number of subjects: 30
Study: 760753

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1000 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (1000 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urinary excretion of free and conjugated paracetamol
Number of subjects: 12
Study: 30807834

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with low intensity laser (InGaAlP) and 0.005% methylene blue photosensitizer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Selective caries removal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no aPDT)
Number of subjects: 20
Study: 28133925

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg intravenously on days 1, 15, 29, and week 8)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 49
Study: 25265472

Group type: EXPERIMENTAL
Intervention: peginterferon beta‐1a 125 μg every 2 weeks
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: peginterferon beta‐1a 125 μg every 4 weeks
Number of subjects: 1512

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1512
Study: 23425501

Group type: EXPERIMENTAL
Intervention: Early surgery (<48 hours)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 76
Study: 21883125

Group type: EXPERIMENTAL
Intervention: Bristol group (fentanyl 1-2 μg.kg(‐1) and diclofenac 1-2 mg.kg(‐1))
Number of subjects: 65

Group type: COMPARATOR
Intervention: Codeine group (codeine 1.5 mg.kg(‐1))
Number of subjects: 65
Study: 19210151

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/320 mg once daily (o.d.)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Amlodipine/valsartan 2.5/160 mg o.d. (initial treatment)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo, amlodipine, valsartan, or combination therapy (core study)
Number of subjects: 403
Study: 16632278

Group type: EXPERIMENTAL
Intervention: Caries 1 or 2 filters for periapical images
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Periodontal 1 or 2 filters for panoramic images
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional radiographs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nonfiltered and Noise Reduction-filtered images
Number of subjects: 20
Study: 15509930

Group type: EXPERIMENTAL
Intervention: Modified mattress suture technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hinderer technique
Number of subjects: 50
Study: 11729578

Group type: EXPERIMENTAL
Intervention: Dead Sea bath salt
Number of subjects: 23

Group type: COMPARATOR
Intervention: Common salt
Number of subjects: 23
Study: 9270664

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 2 g/kg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7525790

Group type: EXPERIMENTAL
Intervention: Chemotherapy with hyperthermia (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy alone (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chemotherapy with hyperthermia (group B) excluding T1 tumours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy alone (group A) excluding T1 tumours
Number of subjects: 40
Study: 3669679

Group type: EXPERIMENTAL
Intervention: Abstain from drinking for 2 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Maintain usual drinking patterns for 2 weeks
Number of subjects: 170